| Revised Full Year 2025 Guidance: | |||||
| Full Year 2025 Guidance | Previous Full Year 2025 Guidance | 2024 Actual | Growth | ||
| Net Revenue (Total Company) | $756 million - $776 million | $739 million - $759 million | $614 million | 23% - 26% | |
| Cortrophin Gel Net Revenue | $265 million - $274 million | n/p | $198 million | 34% - 38% | |
| ILUVIEN and YUTIQ Net Revenue | $97 million - $103 million | n/p | $32 million | n/m | |
| Adjusted Non-GAAP EBITDA | $190 million - $200 million | $182 million - $192 million | $156 million | 22% - 28% | |
| Adjusted Non-GAAP Diluted EPS | $6.12 - $6.49 | n/p | $5.20 | 18% - 25% | |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.